English | Español

Janssen Biotech, Inc.
Nicholas Gueguen | Aug 17, 2017

FDA gives Imbruvica go-ahead to aid patients with chronic graft versus host disease
Jamie Barrand | Mar 9, 2016

FDA approves Imbruvica as first-line therapy for chronic lymphocytic leukemia
Jamie Barrand | Sep 17, 2015

Janssen's multiple myeloma drug accepted for FDA priority review

Trending
+ Pharmaceuticals
Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program
+ Pharmaceuticals
Patient Daily | Sep 22, 2025

Nurses United for Healthcare Integrity says hospitals abuse 340B drug pricing program
Patient Daily | Sep 19, 2025

ENT specialist on ongoing chronic sinus cases: ‘Some of it could be incomplete surgery’
+ Pharmaceuticals
Patient Daily | Sep 22, 2025

Staff Attorney of Legal Aid Society on 340B: 'Hospitals are exploiting the 340B program'